Therapeutic Response

v::RET status confers therapeutic sensitivity to Selpercatinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Retevmo (selpercatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to selpercatinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test.
Retsevmo (selpercatinib) [product information]. EMA. The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult patients with advanced RET fusion-positive non-small cell lung cancer not previously treated with a RET inhibitor.